Previous 10 | Next 10 |
home / stock / nvs / nvs articles
Novartis AG (NYSE: NVS) announced topline results from the pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study at nine months of...
Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in ...
JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid im...
Centene Corporation (NYSE: CNC) is reportedly laying off about 3% of its workforce as the health insurer plans to cut expenditures and acceler...
Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it e...
Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroe...
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially ...
Bloomberg Amazon Poaches Microsoft's Product Chief Ahead Of Its Annual Devices Event After Microsoft Corp (NASDAQ: MSFT) Chief Produ...
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, fr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...